Initial Public Offering
Baird served as co-manager on this offering
AboutARMO BioSciences, Inc. (“ARMO” or the “Company”) (NASDAQ-GS:ARMO) recently completed an initial public offering of 8,658,823 shares of its common stock at a price of $17.00 per share for total gross proceeds of approximately $147.2 million, which includes the exercise in full by the underwriters of their option to purchase an additional 1,129,411 shares of common stock at the public offering price.
ARMO is a late-stage immuno-oncology company that is developing a pipeline of novel, proprietary product candidates that activate the immune system of cancer patients to recognize and eradicate tumors. The Company's lead product candidate, AM0010 (pegilodecakin), is being evaluated in an ongoing Phase 1/1b clinical trial as a therapy for pancreatic cancer, non-small cell lung cancer, renal cell carcinoma, colorectal carcinoma and melanoma. In addition, AM0010 is being evaluated in a Phase 3 randomized pivotal clinical trial in pancreatic cancer patients, which compares a combination of AM0010 and FOLFOX (standard of care chemotherapy regimen) to FOLFOX alone, as a second-line therapy after tumor progression during or following a gemcitabine-containing regimen. The Company also has a number of other immuno-oncology product candidates aimed at treating a variety of cancers in combination with standard of care treatments and emerging immunotherapies. These candidates are in various stages of pre-clinical development, and include: AM0001, an anti-PD-1 checkpoint inhibitor; AM0003, an anti-LAG-3 checkpoint inhibitor; AM0015, a form of recombinant human Interleukin-15 (IL-15) cytokine; and AM0012, a form of recombinant human Interleukin-12 (IL-12) cytokine. ARMO is located in Redwood City, California.
CONTACT US TO LEARN MORE
- January 2018
- ARMO BioSciences, Inc.
- Target Location
- North America